<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970537</url>
  </required_header>
  <id_info>
    <org_study_id>202105202</org_study_id>
    <nct_id>NCT04970537</nct_id>
  </id_info>
  <brief_title>Efficacy Analysis of Tigecycline-based Therapy and Polymyxin B-based Therapy in ICU Infection</brief_title>
  <official_title>Efficacy Analysis of Tigecycline-based Therapy and Polymyxin B-based Therapy in ICU Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological&#xD;
      indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis&#xD;
      and other discharge information of patients receiving tigecycline or polymyxin B admitted to&#xD;
      the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from&#xD;
      2017 to 2021 were included.&#xD;
&#xD;
      To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic&#xD;
      regimens and their effect on the prognosis of patients, and to conduct subgroup analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological&#xD;
      indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis&#xD;
      and other discharge information of patients receiving tigecycline or polymyxin B admitted to&#xD;
      the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from&#xD;
      2017 to 2021 were included. The four hospitals included the 1st-3th XiangYa Hospitals and&#xD;
      Hunan Provincial People's Hospital. Organize the data.Patients with a course of treatment &lt; 4&#xD;
      days and shedding were excluded.To analyze the therapeutic effect of tigecycline-based or&#xD;
      polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to&#xD;
      conduct subgroup analysis. The chi-square test was used for the counting data, and the&#xD;
      Mann-Whitney U test or Kruskal-Wallis H test was used for the measurement data. The&#xD;
      significance value was adjusted by Bonferroni correction method for multiple tests, and the P&#xD;
      was tested on both sides,P&gt;0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hospital mortality rate</measure>
    <time_frame>up to hospital discharge or die in hospital, up to 48 weeks(estimation).</time_frame>
    <description>Patients die in hospital or abandon treatment due to poor prognosis in hospital after treatment of tigecycline or polymyxin B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>30d mortality rate</measure>
    <time_frame>up to the 30th day of the treatment of tigecycline or polymyxin B</time_frame>
    <description>Patients die after treatment of tigecycline or polymyxin B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial clearance rate</measure>
    <time_frame>from the first day of the treatment of tigecycline or polymyxin B until to the end day, up to 8 weeks (estimation).</time_frame>
    <description>Bacterial clearance during treatment of tigecycline or polymyxin B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The length of hospital stay</measure>
    <time_frame>up to hospital discharge or die in hospital, up to 48 weeks (estimation).</time_frame>
    <description>The length of hospital stay,days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of ICU stay</measure>
    <time_frame>up to hospital discharge or die in hospital, up to 24 weeks (estimation).</time_frame>
    <description>The length of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization Cost</measure>
    <time_frame>up to hospital discharge or die in hospital, up to 48 weeks (estimation).</time_frame>
    <description>total Hospitalization Cost</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine</measure>
    <time_frame>at the end day of the treatment of tigecycline or polymyxin B, up to 8 weeks (estimation).</time_frame>
    <description>serum creatinine at the end day of the treatment of tigecycline or polymyxin B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MV days</measure>
    <time_frame>up to hospital discharge or die in hospital, up to 48 weeks (estimation).</time_frame>
    <description>the total days with mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VA days</measure>
    <time_frame>up to hospital discharge or die in hospital, up to 48 weeks (estimation).</time_frame>
    <description>the total days with vasoactive agent</description>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Tigecycline</condition>
  <condition>Polymyxin B</condition>
  <condition>Intensive Care Unit</condition>
  <eligibility>
    <study_pop>
      <textblock>
        14-95 year-old patients in ICU, who received tigecycline and polymyxin B treatment (â‰¥4d).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ICU patients receiving tigecycline or polymyxin B treatment;&#xD;
&#xD;
          -  Age 14-95, gender unlimited;&#xD;
&#xD;
          -  there are clear infections and strains;&#xD;
&#xD;
          -  The patient and/or his/her family agree to sign the informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with treatment of less than 4 days;&#xD;
&#xD;
          -  patients with abscission;&#xD;
&#xD;
          -  Pregnant patients;&#xD;
&#xD;
          -  Patients with age &lt; 14 years or &gt; 95 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuangping Zhao</last_name>
    <role>Study Chair</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuangping Zhao</last_name>
    <phone>13974953002</phone>
    <email>zsping8888@sina.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangya Hospital of Central south university</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuangping Zhao</last_name>
      <phone>13974953002</phone>
      <email>zsping8888@sina.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 4, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

